ArticleInternational journal of molecular medicine2020
Fibroblast‑derived exosomal microRNA‑369 potentiates migration and invasion of lung squamous cell carcinoma cells via NF1‑mediated MAPK signaling pathway.
Article in International journal of molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 41 citations in OpenAlex.
- Review
- The role of the tumor microenvironment in drug resistance acquisition in lung squamous cell carcinoma.Journal of experimental & clinical cancer research : CR · 2026Review
- Low Tumor miR-369-3p Levels Combined with Plasma Hepatitis B Virus Pre-S2 Gene Deletion Mutation Predict Higher Hepatocellular Carcinoma Recurrence.Journal of hepatocellular carcinoma · 2026Article
- Engineered MSC-Exosomes Delivering miRNAs for Respiratory Disease Diagnostics and Therapy: Opportunities and Challenges.International journal of nanomedicine · 2026Review
- Exosomal microRNA Panels for Detecting Early-Stage Non-Small Cell Lung Cancer.Diagnostics (Basel, Switzerland) · 2025Article
- Hidden forces: the impact of cancer-associated fibroblasts on non-small cell lung cancer development and therapy.Journal of translational medicine · 2025Review
- Review
- Harnessing EVs-ncRNA for Lung Cancer: From Oncogenic Pathways to Novel Diagnostic and Therapeutic Strategies.International journal of nanomedicine · 2025Review
- CAF-derived exosome-miR-3124-5p promotes malignant biological processes in NSCLC via the TOLLIP/TLR4-MyD88-NF-κB pathway.Oncology research · 2025Article
- Review
- Exosomal miRNAs: the tumor's trojan horse in selective metastasis.Molecular cancer · 2024Review
- The hidden messengers: cancer associated fibroblasts-derived exosomal miRNAs as key regulators of cancer malignancy.Frontiers in cell and developmental biology · 2024Review
- Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives.Cancer communications (London, England) · 2023Review
- Cancer-associated fibroblasts derived extracellular vesicles promote angiogenesis of colorectal adenocarcinoma cells through miR-135b-5p/FOXO1 axis.Cancer biology & therapy · 2022Article
- Intercellular crosstalk between cancer cells and cancer-associated fibroblasts via extracellular vesicles.Cancer cell international · 2022Review
- MiR-139-3p Targets CHEK1 Modulating DNA Repair and Cell Viability in Lung Squamous Carcinoma Cells.Molecular biotechnology · 2022Article
- Emerging function and clinical significance of extracellular vesicle noncoding RNAs in lung cancer.Molecular therapy oncolytics · 2022Review
- Cancer-Associated Fibroblasts Influence the Biological Properties of Malignant Tumours via Paracrine Secretion and Exosome Production.International journal of molecular sciences · 2022Review
- Extracellular Vesicles Derived from Lung Cancer Cells Induce Transformation of Normal Fibroblasts into Lung Cancer-Associated Fibroblasts and Promote Metastasis of Lung Cancer by Delivering lncRNA HOTAIR.Stem cells international · 2022Article
- circCNN2 Accelerates Cell Proliferation and Invasion in Lung Squamous Cell Carcinoma via Regulating miR-184/E2F1 and Activating MAPK Signaling Pathway.Disease markers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer‑associated fibroblasts (CAFs) exhibit tumor‑stimulating properties and are associated with poor survival in several types of cancer, making them potential therapeutic targets. The present study aimed to determine whether CAFs were associated with cell migration and invasion in lung squamous cell carcinoma (LUSC), as well as their association with microRNA‑369 (miR‑369) in these processes. Firstly, the changes of the malignant biological behavior were observed by treating the LUSC cells with the CAFs‑derived extracellular vesicles (CAFs‑EVs). Subsequently, the differentially expressed miRNAs in the cells treated with CAFs‑EVs were analyzed by microarray analysis. Following inhibition of miR‑369 expression in CAFs‑EVs, LUSC cells were co‑cultured, and the malignant biological behavior of the cells was re‑examined. Then, through bioinformatics analysis and verification, the mRNA targets of miR‑369 and the corresponding downstream signaling pathway were screened out. Finally, the effects of CAFs‑EVs on the growth and metastasis of LUSC were demonstrated by in vivo tumor formation and metastasis experiments. It was identified that miR‑369 was expressed at a relatively high level in the CAFs‑EVs. Neurofibromin‑1 (NF1) was hypothesized as a direct target of miR‑369 in LUSC. Also, the overexpression of miR‑369 activated the mitogen‑activated protein kinase signaling pathway by interacting with NF1, consequently potentiating LUSC cell growth. The present study provided novel insights into the action of miR‑369 in CAFs‑EVs in controlling LUSC cell migration, invasion and tumorigenesis, and identified miR‑369 in CAFs‑EVs as an important prognostic marker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.